NASDAQ:AIMT - Aimmune Therapeutics Stock Price, Forecast & News

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.03). During the same period in the prior year, the company earned ($0.89) earnings per share. View Aimmune Therapeutics' Earnings History.

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Aimmune Therapeutics.

Aimmune Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 analysts have issued 12 month target prices for Aimmune Therapeutics' stock. Their forecasts range from $27.00 to $81.00. On average, they anticipate Aimmune Therapeutics' share price to reach $48.82 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.

News stories about AIMT stock have trended neutral recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Aimmune Therapeutics.

Aimmune Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 11,570,000 shares, an increase of 6.4% from the January 15th total of 10,870,000 shares. Based on an average trading volume of 888,400 shares, the short-interest ratio is currently 13.0 days. Approximately 29.0% of the company's shares are short sold. View Aimmune Therapeutics' Current Options Chain.

Some companies that are related to Aimmune Therapeutics include Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE) and Zai Lab (ZLAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), CA (CA), Amarin (AMRN), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK) and Roku (ROKU).

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Aimmune Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (5.39%), FMR LLC (4.59%), State Street Corp (3.51%), Victory Capital Management Inc. (3.44%), Victory Capital Management Inc. (3.41%) and Alliancebernstein L.P. (3.30%). Company insiders that own Aimmune Therapeutics stock include Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman and Stephen George Dilly. View Institutional Ownership Trends for Aimmune Therapeutics.

AIMT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Massachusetts Financial Services Co. MA, Palo Alto Investors LP, UBS Group AG, Alliancebernstein L.P., State of New Jersey Common Pension Fund D, Citigroup Inc. and Rice Hall James & Associates LLC. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman and Douglas T Sheehy. View Insider Buying and Selling for Aimmune Therapeutics.

AIMT stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp, FMR LLC, Fiera Capital Corp, New York State Common Retirement Fund, Bank of America Corp DE and Geode Capital Management LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Eric Bjerkholt, Jayson Donald Alexander Dallas and Kathryn E Falberg. View Insider Buying and Selling for Aimmune Therapeutics.

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AIMT stock can currently be purchased for approximately $26.02.

Aimmune Therapeutics has a market capitalization of $1.63 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.View Additional Information About Aimmune Therapeutics.

The official website for Aimmune Therapeutics is http://www.aimmune.com/.

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]